Arcadia Biosciences (RKDA) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RKDA shares.
View RKDA analyst ratings or view top-rated stocks.

1 equities research analysts have issued 12-month price targets for Arcadia Biosciences' stock. Their RKDA share price forecasts range from $18.00 to $20.00. On average, they predict the company's stock price to reach $19.00 in the next year. This suggests a possible upside of 313.9% from the stock's current price.
View analysts price targets for RKDA or view top-rated stocks among Wall Street analysts.

Arcadia Biosciences' stock was trading at $0.2710 at the start of the year. Since then, RKDA stock has increased by 1,593.7% and is now trading at $4.59.
View the best growth stocks for 2023 here.

Arcadia Biosciences saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 12,400 shares, a decline of 69.8% from the April 30th total of 41,000 shares. Based on an average daily trading volume, of 167,500 shares, the short-interest ratio is presently 0.1 days. Approximately 2.1% of the company's stock are short sold.
View Arcadia Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our RKDA earnings forecast.

Arcadia Biosciences, Inc. (NASDAQ:RKDA) posted its earnings results on Thursday, March, 30th. The basic materials company reported ($6.31) earnings per share (EPS) for the quarter. The basic materials company earned $1 million during the quarter. Arcadia Biosciences had a negative net margin of 245.87% and a negative trailing twelve-month return on equity of 63.53%.

Shares of Arcadia Biosciences reverse split before market open on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

(RKDA) raised $66 million in an IPO on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO.

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

Arcadia Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Armistice Capital LLC (9.62%), Sabby Management LLC (6.16%), State Street Corp (1.42%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Pamela Haley, Stanley Jacot Jr and Thomas J Schaefer.
View institutional ownership trends.

Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RKDA stock can currently be purchased for approximately $4.59.

Arcadia Biosciences (NASDAQ:RKDA) has a market capitalization of $3.95 million and generates $9.96 million in revenue each year. The basic materials company earns $-15,380,000.00 in net income (profit) each year or ($28.77) on an earnings per share basis.

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The official website for the company is www.arcadiabio.com. The basic materials company can be reached via phone at (530) 756-7077, via email at ir@arcadiabio.com, or via fax at 530-756-7027.